However, it must not be forgotten that targeting IL-12 together with IL-23 has become an established therapeutic strategy in IBD, psoriasis and peripheral spondylo-arthritis, while experiences with anti-p19 antibodies are still limited. The gene discussed is IL23A; the disease is inflammatory bowel disease.